The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer (NYSE: PFE) has hit a bit of a rough patch, after doing well with its COVID vaccine and Paxlovid treatment. The ...

Valentina Dabos, lead author of the tracker, said in a statement that the consequences of bankruptcies in healthcare "can be ...

Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe ...

In the months after the 2024 election and before President Donald Trump’s second inauguration, healthcare executives paid million of dollars to get the ear of the president.

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...